Closing regulatory gaps and protecting consumers from unapproved drug formulations
Indiana’s 2026 legislation establishes a proactive, pro-compliance framework aligned with federal compounding standards. The law preserves access to legitimate obesity treatments while instituting supply-chain guardrails, medical spa oversight, and transparent adverse-event reporting. Such supply chain protections improve regulators’ ability to detect unsafe practices and trace harms from mass compounded products back to their source.
Legitimate drug compounding is intended to temporarily address FDA-official shortages or customize medications for specific patient medical needs, such as documented dye allergies. Indiana’s framework strengthens product-quality oversight by:
• Requiring compounders to source bulk drug substances, often called Active Pharmaceutical Ingredients or APIs, exclusively from FDA-registered facilities authorized for human drug manufacturing, excluding research- or veterinary-grade ingredients.
• Mandating a Certificate of Analysis verifying identity, content, and country of origin for each bulk drug shipment; quality control testing of the bulk API must be conducted.
• Granting the Board of Pharmacy investigative authority over ingredient sourcing, storage, handling, labeling, and compounding – including out-of-state facilities shipping into the state.
Indiana’s framework demonstrates how states can preserve access to obesity and metabolic therapies while closing critical patient-safety gaps, providing a practical template for legislatures modernizing healthcare safeguards as biologic treatments expand.
Medical spas are a growing source of prescription obesity treatments but historically face little to no state oversight. Indiana’s policy mandates that medical spas offering healthcare or lifestyle prescription treatments must register with the Medical Licensing Board and designate a responsible, licensed practitioner to oversee operations, verify staff credentials, and ensure care stays within appropriate scope of practice.
To ensure regulators and advocates can detect unsafe practices and trace potential harms back to their source, the Indiana model incorporates key accountability measures:
Facilities must report any serious adverse event involving death, life-threatening injury, hospitalization, or surgical intervention within 15 days.
The State Department of Health publishes twice-yearly reports on compounding oversight, inspection deficiencies, investigations, and disciplinary actions.
The law bans medical spas from performing prescription treatments or procedures at transient off-site locations, including hotel suites and private parties.
State fiscal analyses confirm that implementation costs are minimal. Medical spa licensing fees and civil penalties—including administrative fines up to $5,000 per violation for unregistered operations—help offset enforcement costs, offering other state legislatures an easily adaptable, fiscally sound policy model.
Would you like to contact DPAC to work on legislation in your state? Drop us a line.
